Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6209 in Combination With Other Antitumor Therapies in Advanced Breast Cancer or HRS-9813 as Monotherapy in Advanced Solid Tumors
NCT06555068Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-6209, HRS-9813 in breast cancer, solid tumor, sponsored by Hengrui. Started Aug 2024; status: recruiting.
02
Drugs
HRS-6209HRS-9813
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06555068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555068.